Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

HISTORICAL FACTS: Heres what to expect from regeneron pharmaceuticals next earnings report - Caught on Camera

Valued at a market cap of $68.8 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, and commercializes antibody-based medicines for serious diseases. Headquartered in Tarrytown, New York, the company is known for leveraging its proprietary genetic research and antibody technologies to develop innovative therapies.

REGN is scheduled to announce its fiscal Q2 earnings for 2026 before the market opens on Thursday, July 30. Ahead of the release, analysts expect this healthcare company to report a profit of $8 per share, down 25.4% from $10.72 per share in the year-ago quarter. The company has topped Wall Street’s bottom-line estimates in each of the last four quarters.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.